Shareholder Class Action

WILMINGTON, Del. — Shareholders claim directors of Foundation Medicine filed a false and misleading registration statement about its proposed sale to Roche Pharmaceuticals, for $137 a share or $2.4 billion, in a federal class action.

%d bloggers like this: